<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prader-Willi syndrome: Management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prader-Willi syndrome: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prader-Willi syndrome: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charlotte Höybye, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ann O Scheimann, MD, MBA</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mitchell E Geffner, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melvin B Heyman, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Prader-Willi syndrome (PWS) is a neurodevelopmental condition attributed to genetic imprinting and caused by absence of expression of the paternally active genes on the long arm of chromosome 15 (15q11.2-q13). The vast majority of cases occur sporadically. It is a hypothalamic disease and the most common syndromic form of obesity.</p><p>The management of PWS will be reviewed here. The clinical features and diagnosis of this disorder are discussed separately. (See  <a class="medical medical_review" href="/d/html/5875.html" rel="external">"Prader-Willi syndrome: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H660967640"><span class="h1">FEEDING AND OBESITY</span><span class="headingEndMark"> — </span>PWS is characterized by an initial phase of hypotonia and poor feeding during infancy, followed by hyperphagia and rapid weight gain beginning during early childhood. Obesity ensues if food intake is not rigorously restricted  (<a class="graphic graphic_table graphicRef140076" href="/d/graphic/140076.html" rel="external">table 1</a>). The different phases of appetite and weight gain are shown in the figure  (<a class="graphic graphic_figure graphicRef140074" href="/d/graphic/140074.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H1397547521"><span class="h2">Infants and children &lt;2 years</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Poor feeding</strong> – Mainly due to the muscular hypotonia, infants with PWS frequently have problems with suck and feeding, with associated hypotonia and poor weight gain. Management includes oromotor evaluation with use of specialized feeding strategies, videofluoroscopic swallow study, and high-calorie feedings. The average duration of tube feeding during the neonatal period is six weeks, which can generally be handled with nasogastric tube use [<a href="#rid1">1</a>]. Speech therapy may assist with development of swallowing, communication, and enunciation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Caloric goals</strong> – Goals for energy intake should be guided by a dietitian and designed to promote moderate rates of weight gain, with appropriate balance of protein and micronutrients with frequent need for vitamin supplementation.</p><p></p><p class="bulletIndent1">Adequate energy intake is important to optimize brain growth and cognitive development (especially prior to three years of age), while excessive energy intake may increase the long-term predisposition to obesity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastroesophageal reflux</strong> – Infants and children with significant gastroesophageal reflux should be managed primarily with lifestyle measures (eg, thickened feeds and positioning) and occasionally pharmacotherapy (acid suppression), similar to individuals without PWS. We advise against surgical intervention (fundoplication) because of potential adverse effects on swallowing, which might exacerbate the risk of choking after hyperphagia develops later in life. (See  <a class="medical medical_review" href="/d/html/5876.html" rel="external">"Gastroesophageal reflux in infants", section on 'Treatment options'</a>.)</p><p></p><p class="headingAnchor" id="H3880652863"><span class="h2">Children and adults</span><span class="headingEndMark"> — </span>Increased appetite typically develops between the ages of three and five years after a period of normal eating and weight gain and subsequently progresses to marked hyperphagia by approximately eight years  (<a class="graphic graphic_figure graphicRef140074" href="/d/graphic/140074.html" rel="external">figure 1</a>). The hyperphagia includes a strong obsession with eating, a feeling of persistent hunger, and decreased satiety. The hyperphagia continues throughout life, leading to a strong predisposition to obesity.</p><p class="headingAnchor" id="H2883046379"><span class="h3">Restriction of food intake</span><span class="headingEndMark"> — </span>Controlling obesity through a food-secure environment and a strict limitation of food intake is a central focus of effective management of PWS.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nutritional goals</strong> – Individuals with PWS have reduced energy needs, likely related to their abnormal body composition, with relatively increased body fat and decreased lean body mass. To achieve and maintain a healthy body weight, caloric goals must often be set well below those predicted for individuals without PWS, typically 70 percent of the needs for individuals without PWS matched for age, sex, and body mass index (BMI) [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1">With these low-calorie diets, vitamin and mineral (calcium) supplementation is usually needed to meet daily requirements. Consultation with a dietitian is important to set appropriate goals for body weight and nutrition to ensure adequate protein intake despite calorie restriction. Gummy vitamin supplements should be avoided due to poor mineral composition, added calories, and risk of overdose if the person with PWS gains access to the supply of the supplement.</p><p></p><p class="bulletIndent1">Monitoring growth and PWS-specific growth charts are discussed below. (See <a class="local">'Monitoring growth'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of hyperphagia</strong> – Food security (restriction) is essential to prevent excessive weight gain and also to reduce the risk of acute complications of hyperphagia, including choking and gastric dilation/rupture (see <a class="local">'Acute complications of hyperphagia'</a> below). Food security using physical barriers (locks) and close supervision is often necessary. Some behavioral modification techniques have been helpful in engaging the cooperation of the patient and in reducing the associated anxiety and distress [<a href="#rid3">3</a>], but these are not sufficient to control food intake.</p><p></p><p class="bulletIndent1">Common behaviors include stealing and hoarding food, even when the individual is otherwise well behaved; some may even eat frozen foods, garbage, or nonfood-related items. Coordination of efforts between the patient's family, caregivers, school, work, and a multidisciplinary care team is valuable. Food security practices should also be employed in the school and work setting. This requires continuing education of teachers and supervisors to maintain food security, avoid using food for behavioral reinforcement, and ensure that activities do not include food preparation and cleanup. For most adults, a specialized and highly structured group home environment is helpful in managing the PWS-associated hyperphagia and obesity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychosocial consequences</strong> – The characteristic hyperphagia of PWS has significant impacts on quality of life and educational/vocational and social functioning. Restriction of food often triggers temper outbursts and is also an important source of burden and stress for the family and caregivers [<a href="#rid4">4,5</a>]. In spite of concerted efforts, many children and adults with PWS will develop or continue to have severe obesity and associated medical problems, which contribute to the emotional and financial burden of the condition.</p><p></p><p class="headingAnchor" id="H2573997349"><span class="h3">Other interventions for obesity</span><span class="headingEndMark"> — </span>Several pharmacotherapies or surgical approaches to treatment of hyperphagia and PWS-associated obesity have been attempted, but due to the rarity of the disease, evidence is limited and the development of many pharmacologic substances terminated in early study phases. The pathophysiologic pathway of the regulation of hunger and satiety in PWS is very complex, and identification of a single substance or specific management that will completely erase hyperphagia might not be realistic.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacotherapy</strong> – Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are established treatments for adolescent and adult patients with obesity and particularly those with type 2 diabetes mellitus. (See  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/5376.html" rel="external">"Obesity in adults: Drug therapy", section on 'GLP-1 receptor agonists'</a> and  <a class="medical medical_review" href="/d/html/5376.html" rel="external">"Obesity in adults: Drug therapy"</a>.)</p><p></p><p class="bulletIndent1">In patients with PWS, GLP-1 RA appear to be somewhat less effective for hemoglobin A1c (A1C) and weight outcomes compared with populations without PWS, but the evidence is limited because of the small size and heterogeneity of the cohorts studied and variable outcomes. A systematic review that included 23 adolescents and adults with PWS and type 2 diabetes mellitus suggested that daily injections of <a class="drug drug_pediatric" data-topicid="132373" href="/d/drug information/132373.html" rel="external">exenatide</a> or <a class="drug drug_pediatric" data-topicid="121884" href="/d/drug information/121884.html" rel="external">liraglutide</a> may reduce BMI and A1C but with marked heterogeneity of response [<a href="#rid6">6</a>]. BMI decreased between 1.5 to 16 kg/m<sup>2</sup> in 10 patients, and A1C decreased 0.3 to 7.5 percent in 19 patients, but not all of the patients responded to the treatment. In contrast, a 16-week randomized trial with liraglutide in 55 children and adolescents with PWS reported no effect on BMI or other weight-related parameters [<a href="#rid7">7</a>]. On the other hand, an improvement in hyperphagia scores was observed during an open-label extension through 52 weeks. Limitations of this trial included a relatively small number of participants and variable treatment exposure time. In a case report of a man with PWS and diabetes, treatment with <a class="drug drug_pediatric" data-topicid="140434" href="/d/drug information/140434.html" rel="external">semaglutide</a> (weekly injections) was associated with a decrease in A1C and weight, whereas liraglutide had not been effective for this individual [<a href="#rid8">8</a>]. The long-term safety of treatment with GLP-1 RA in PWS is not known. In the studies described above, the safety profile was comparable with that in cohorts without PWS. However, GLP-1 RA are known to delay gastric emptying, which is already a problem in PWS, and delayed gastric emptying might theoretically increase the risk of gastric rupture.</p><p></p><p class="bulletIndent1">Intranasal <a class="drug drug_general" data-topicid="8562" href="/d/drug information/8562.html" rel="external">carbetocin</a>, an oxytocin analog with improved specificity for oxytocin receptors, is under investigation. In phase 2 studies, administration of carbetocin to individuals with PWS improved hyperphagia and some other behavioral measures [<a href="#rid9">9</a>]. The results of a phase 3 study showed beneficial effects of carbetocin at a dose of 3.2 mg on hyperphagia scores, anxiety, and caregiver impression of change [<a href="#rid10">10</a>]. However, the outcomes during long-term follow-up with carbetocin did not reach significance. Previous small trials of oxytocin in patients with PWS have produced conflicting results and a possible worsening of behavioral symptoms but might be effective for some individuals [<a href="#rid11">11-13</a>].</p><p></p><p class="bulletIndent1">Other medications targeting hyperphagia are under investigation, including ghrelin analogs, controlled-release <a class="drug drug_pediatric" data-topicid="13224" href="/d/drug information/13224.html" rel="external">diazoxide</a>, <a class="drug drug_pediatric" data-topicid="130246" href="/d/drug information/130246.html" rel="external">setmelanotide</a>, and tesofensine-metoprolol [<a href="#rid14">14,15</a>].</p><p></p><p class="bulletIndent1">Previous trials with <a class="drug drug_pediatric" data-topicid="140793" href="/d/drug information/140793.html" rel="external">phentermine</a> (an anorectic agent), selective serotonin reuptake inhibitors [<a href="#rid16">16</a>], <a class="drug drug_pediatric" data-topicid="12851" href="/d/drug information/12851.html" rel="external">topiramate</a>, and ghrelin analogs showed that these medications were less effective in controlling appetite, hyperphagia, and weight [<a href="#rid17">17-19</a>]. In addition, somatostatin analogs that suppress ghrelin were not effective [<a href="#rid20">20-23</a>]. Studies of beloranib, an angiogenesis inhibitor, showed a significant decrease in hyperphagia and weight, but the studies were terminated because of fatal side effects (pulmonary embolism) [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical weight loss procedures</strong> – Bariatric surgery is considered a treatment option in patients with PWS with extreme obesity and severe complications in whom other treatments have failed.</p><p></p><p class="bulletIndent1">Metabolic weight loss surgery, such as gastric bypass or vertical sleeve gastrectomy, has a limited role in managing obesity in patients with PWS as they do not change the eating behavior (hyperphagia). The limited evidence from small case series suggests modest weight loss during the first year after weight loss surgery, followed by weight regain so that there was little or no effect in long-term follow-up [<a href="#rid25">25,26</a>]. A few series have reported better outcomes, including durable results of weight loss surgery in patients who also received high-intensity home care [<a href="#rid27">27,28</a>].</p><p></p><p class="bulletIndent1">Patients with PWS also may have increased risks after weight loss surgery:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gastric-restrictive procedures may be particularly risky for patients with PWS because of their innate hyperphagia and their predisposition to gastric distention and necrosis. These complications have been reported in patients who underwent intragastric balloon placement or adjustable gastric banding, not after other weight loss surgery procedures [<a href="#rid29">29-31</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Malabsorptive operations result in a lifelong need for supplementation with vitamins and minerals and may have a particularly high risk for patients with PWS because they already have an increased risk for decreased bone mineral density [<a href="#rid29">29</a>] (see <a class="local">'Low bone mineral density'</a> below). This is clearly true for biliopancreatic diversion (which is rarely performed because of high risks for malabsorption); whether gastric bypass has significant nutritional risks in this population has not been established.</p><p></p><p class="bulletIndent1">(See  <a class="medical medical_review" href="/d/html/5880.html" rel="external">"Surgical management of severe obesity in adolescents", section on 'Special populations'</a>.)</p><p></p><p class="headingAnchor" id="H2801560852"><span class="h2">Acute complications of hyperphagia</span></p><p class="headingAnchor" id="H3550171138"><span class="h3">Choking episodes</span><span class="headingEndMark"> — </span>Choking episodes in patients with PWS are common, likely because of hyperphagia and decreased mastication, with impaired oromotor coordination. In a case series of patients who died suddenly, 34 percent of patients had a history of choking episodes and choking was listed as a cause of death in 8 percent of patients [<a href="#rid32">32</a>]. In a systematic review of morbidity and mortality in PWS, 30 of 500 deaths were found to be caused by choking [<a href="#rid33">33</a>]. Training in use of the Heimlich maneuver is recommended for all families and caregivers for PWS patients.</p><p class="headingAnchor" id="H1496840699"><span class="h3">Gastric distension and rupture</span><span class="headingEndMark"> — </span>Acute gastric distension occasionally develops in individuals with PWS, sometimes with associated necrosis and gastric rupture, as described in several case reports and an autopsy study [<a href="#rid34">34,35</a>]; in two reviews, it was reported to be the cause of death in 10 percent of the patients [<a href="#rid33">33,36</a>].</p><p>An episode of gastric distension typically presents with progressive abdominal discomfort, abdominal distention, and vomiting. Patients may only complain of mild abdominal discomfort despite significant gastric necrosis, which is consistent with the difficulties with expressing their well-being and the high pain threshold often reported in patients with PWS. The disorder may be triggered by binge eating episodes, or related to delayed gastric emptying without binge eating, and may be recurrent. The vomiting is often present in the syndrome of acute gastric distension, whereas it is uncommon after episodes of binge eating. A <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.pwsausa.org%2Fwp-content%2Fuploads%2F2015%2F10%2FPWS-GI-Algorithm-Chart.pdf&amp;token=piYIABGVAf9PLq9lwQ7ieiN8wrG34a3%2BvwrClwILUFTChdXP4VtpcXaD0UI7XezJyH6sAbMcpzpuHuG9HJmlNG9jelfJP8mLbN%2BjVFnv5Q%2BtFzOaCDykHGElQTUSgjKV&amp;TOPIC_ID=5864" target="_blank">management algorithm</a> was developed by the clinical advisory board of the Prader-Willi Syndrome Association USA.</p><p class="headingAnchor" id="H135845280"><span class="h1">BEHAVIOR AND NEURODEVELOPMENT</span></p><p>Common behavioral and neurodevelopmental issues and potential interventions are  (<a class="graphic graphic_table graphicRef140076" href="/d/graphic/140076.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Motor skills</strong> – Intensive physical and occupational therapies can assist with muscle tone and strength. Early initiation of <a class="drug drug_pediatric" data-topicid="13354" href="/d/drug information/13354.html" rel="external">recombinant human growth hormone</a> (rhGH) also improves physical function, strength, and motor development (see <a class="local">'Recombinant growth hormone treatment'</a> below). Screening for carnitine deficiency and supplementation if present may be beneficial to help with endurance [<a href="#rid37">37</a>]. Due to the lifelong muscular hypotonia, regular physical activity is important at any age. It might be difficult to find physical activity that patients can adhere to, but most like to walk, swim, or ride a bike. Physical activity is also important for training balance and increasing energy expenditure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Behaviors</strong> – Common behavioral manifestations are temper tantrums; stubbornness; and repetitive, ritualistic, and obsessive-compulsive behaviors that can impede performance in school and at work [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1">Some of these behaviors are similar to those found in autism spectrum disorder. In a systematic review, behaviors meeting criteria for autism spectrum disorder were found in 27 percent of individuals with PWS [<a href="#rid39">39</a>]. One publication has linked autistic-type behaviors to variants of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F605283&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypp0Be4ObtOgDTJqB%2FFR22w&amp;TOPIC_ID=5864" target="_blank"><i>MAGEL2</i></a> gene located within the PWS locus [<a href="#rid40">40</a>]. Other studies suggest that these behaviors are particularly common in PWS caused by uniparental disomy [<a href="#rid39">39,41,42</a>]. (See  <a class="medical medical_review" href="/d/html/5875.html" rel="external">"Prader-Willi syndrome: Clinical features and diagnosis", section on 'Mutation identification'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin picking</strong> – Skin picking and rectal gouging behaviors are common and may respond to treatment with <a class="drug drug_pediatric" data-topicid="13239" href="/d/drug information/13239.html" rel="external">N-acetylcysteine</a> [<a href="#rid16">16,18,43</a>]. <a class="drug drug_pediatric" data-topicid="15555" href="/d/drug information/15555.html" rel="external">Guanfacine</a> has shown benefit for skin picking in one study [<a href="#rid44">44</a>]. In some cases, the rectal picking leads to rectal bleeding and ulceration sufficient to cause anemia or mimic colitis [<a href="#rid45">45</a>]. If anxiety or distress appear to be a trigger for these behaviors, treatment with a selective serotonin reuptake inhibitor can be tried.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychiatric disorders</strong> – A variety of psychiatric symptoms and disorders have been reported among adults, including mood disorders and florid psychotic states [<a href="#rid18">18,46,47</a>]. Approximately 60 percent of patients with PWS due to uniparental disomy may develop psychotic illness by adulthood. The diagnosis of psychosis and initiation of antipsychotic pharmacotherapy should preferably be made in consultation with a psychiatrist. A lower starting dose of antipsychotics with a gradual dose increase is recommended because it is not known how these drugs act on the neurotransmitter systems in the brains of patients with PWS. Another concern is that most antipsychotics cause metabolic changes and promote weight gain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cognition and learning</strong> – A mild to moderate degree of cognitive impairment is a commonly associated characteristic. In one study, the mean intelligence quotient (IQ) of individuals with PWS was 60 [<a href="#rid48">48</a>]. The range of IQs is normally distributed; thus, approximately 5 percent of individuals with PWS will have IQs in the low-normal range (&gt;85) and 5 percent will have severe intellectual disability [<a href="#rid49">49</a>]. Some patients can have a normal IQ within certain areas and low IQ within others. Common deficits are in executive function and socialization. Adults tend to experience cognitive decline with age; in one study, the brain age was 8.74 years older than chronologic age [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/d/html/5875.html" rel="external">"Prader-Willi syndrome: Clinical features and diagnosis", section on 'Adulthood'</a> and  <a class="medical medical_review" href="/d/html/6191.html" rel="external">"Intellectual disability (ID) in children: Management, outcomes, and prevention"</a>.)</p><p></p><p class="bulletIndent1">Most children need individualized education in small classes with limited distraction, although some manage education in common schools, at least during the first few years. Adults usually manage a sheltered or adapted work with low expectancy for delivery and with small demands.</p><p></p><p class="headingAnchor" id="H560517621"><span class="h1">HYPOTHALAMIC AND PITUITARY DYSFUNCTION</span><span class="headingEndMark"> — </span>PWS is a hypothalamic disease, and most patients exhibit evidence of hypothalamic and pituitary dysfunction that includes growth hormone (GH) deficiency (which contributes to short stature and altered body composition), hypogonadism (causing cryptorchidism and delayed puberty), and hypothyroidism [<a href="#rid16">16,51,52</a>]. In contrast, central adrenal insufficiency (corticotropin deficiency) is rare [<a href="#rid16">16,53-55</a>].</p><p>Secretion and regulation of vasopressin concentrations appear to be normal [<a href="#rid16">16</a>], while a reduction in oxytocin-secreting neurons (number and volume) in the paraventricular nucleus in adults with PWS has been shown [<a href="#rid56">56</a>]. The endocrine effects of oxytocin (uterine contractions and milk ejection) are not well studied in PWS. Oxytocin also has a neuroregulatory function with anorectic effects, control of satiety, and glucose intake [<a href="#rid12">12,13,16</a>]; these effects are described above. Management is outlined below  (<a class="graphic graphic_table graphicRef140076" href="/d/graphic/140076.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H3904228972"><span class="h2">Growth hormone deficiency</span><span class="headingEndMark"> — </span>GH deficiency is present in approximately 80 percent of children and 25 to 70 percent of adults with PWS [<a href="#rid16">16,57,58</a>]. It appears to be a primary abnormality of PWS rather than a biochemical phenomenon, as also occurs in obesity unrelated to PWS [<a href="#rid16">16,59</a>]. This is suggested by the associated hypothalamic dysfunction and low insulin-like growth factor 1 (IGF-1) levels present in patients with PWS [<a href="#rid16">16</a>]. In contrast, in simple obesity unrelated to PWS, IGF-1 levels are usually normal.</p><p class="headingAnchor" id="H2196338914"><span class="h3">Monitoring growth</span><span class="headingEndMark"> — </span>Children with PWS should be closely monitored for linear growth by measuring length/height at least every three months and calculating height velocity. A subnormal height velocity usually is the first and most sensitive sign of growth failure (see  <a class="medical medical_review" href="/d/html/5834.html" rel="external">"Diagnostic approach to children and adolescents with short stature", section on 'Is the child's height velocity impaired?'</a>). If the child has evidence of growth failure, they are likely to have GH deficiency. However, other causes of growth failure should be excluded, including hypothyroidism and undernutrition (if the child is young and failing to thrive or on a low-calorie diet).</p><p>Growth charts have been developed for individuals with PWS; these may be helpful for tracking growth relative to other children with and without PWS:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children &lt;3 years</strong> – Charts depicting growth <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5922433%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F9WyS2%2BmbISD1cPa9SCgRnci8vyKZ2%2Fmnf2fB28fHUVWVGZ0IY2CXsZsS6ngLNEjsA%3D%3D&amp;TOPIC_ID=5864" target="_blank">with recombinant human growth hormone (rhGH) treatment</a> [<a href="#rid60">60</a>] and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3065075%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F9WyS2%2BmbISD1cPa9SCgRnci8vyKZ2%2Fmnf2fB28fHUVWFp%2FXfl2GBMfzxdf4oUC9xw%3D%3D&amp;TOPIC_ID=5864" target="_blank">without rhGH treatment</a> [<a href="#rid61">61</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children 3 to 18 years</strong> – Charts depicting growth <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5922433%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F9WyS2%2BmbISD1cPa9SCgRnci8vyKZ2%2Fmnf2fB28fHUVWVGZ0IY2CXsZsS6ngLNEjsA%3D%3D&amp;TOPIC_ID=5864" target="_blank">with rhGH treatment</a> [<a href="#rid60">60</a>] and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4279067%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F9WyS2%2BmbISD1cPa9SCgRnci8vyKZ2%2Fmnf2fB28fHUVWQOZ2GQAhiNZmPYe34eeYqw%3D%3D&amp;TOPIC_ID=5864" target="_blank">without rhGH treatment</a> [<a href="#rid62">62</a>]</p><p></p><p>Some clinicians also use standard growth charts for tracking growth in children with PWS during rhGH treatment, while recognizing that these children tend to have somewhat reduced growth potential than children without PWS, even with rhGH treatment.</p><p class="headingAnchor" id="H26"><span class="h3">Recombinant growth hormone treatment</span><span class="headingEndMark"> — </span>rhGH is routinely included in the management of individuals with PWS because of its potential beneficial effects on linear growth, body composition/obesity, physical function, and cardiovascular risk factors.</p><p>Decisions about initiating rhGH should be made collaboratively with the family or guardian. The discussion should include the potential benefits of rhGH for PWS patients, as well as the treatment burden (subcutaneous injections and cost) and potential risks for this population, as discussed in the following sections.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and timing</strong> – We recommend treatment with rhGH for all children with PWS. We also suggest rhGH therapy during the transition period (ie, between late adolescence and young adulthood) and for adults (although this is an off-label use for adults with PWS in most countries unless there is confirmed or reconfirmed GH deficiency) [<a href="#rid59">59</a>]. Contraindications to rhGH include severe obesity, uncontrolled diabetes, untreated severe sleep apnea or acute respiratory infection, as well as active cancer or psychosis [<a href="#rid23">23</a>]. Patients should be evaluated for these prior to starting treatment and should be monitored during treatment, as outlined below.</p><p></p><p class="bulletIndent1">Formal testing for GH deficiency in children with PWS is not necessary. In contrast, confirming or reconfirming GH deficiency in adolescents and adults is required in most countries before continuing rhGH treatment, although the majority will have GH deficiency if they are tested. Measurement of IGF-1 can help support a diagnosis of GH deficiency if low and is also used for dose titration. Measurement of IGF-binding protein 3 (IGFBP-3) is used by some endocrinologists as evidence of GH deficiency. (See  <a class="medical medical_review" href="/d/html/16539.html" rel="external">"Growth hormone treatment during the transition period"</a> and  <a class="medical medical_review" href="/d/html/6641.html" rel="external">"Growth hormone deficiency in adults"</a>.)</p><p></p><p class="bulletIndent1">In children with PWS, treatment with rhGH should be initiated at the time that PWS is first diagnosed, after adequate nutrition is ensured, and, ideally, prior to one year of age [<a href="#rid63">63</a>]. Early initiation of rhGH improves clinical outcomes, as detailed in the following sections. However, early initiation of rhGH could be difficult in the United States, where growth failure is stipulated as part of the indication for rhGH treatment in PWS and is thus a requirement for coverage by many insurance plans [<a href="#rid64">64</a>]. Growth failure in children is typically defined by the standards used for children without PWS (decreased height velocity or decreased height compared with the mid-parental height prediction) (see  <a class="medical medical_review" href="/d/html/5834.html" rel="external">"Diagnostic approach to children and adolescents with short stature", section on 'Evaluation of growth'</a>). However, for infants and children with PWS who do not meet criteria for growth failure, formal testing for GH deficiency may assist the pediatric endocrinologist and family in making decisions about early initiation of rhGH for treatment of the consequences of GH deficiency other than linear growth. Interpretation of tests for GH deficiency can be a challenge due to the possibility of false-positive (low) results in patients with obesity; however, a low IGF-1 in the setting of growth failure with normal or excessive weight is very suggestive of GH deficiency. (See  <a class="medical medical_review" href="/d/html/5842.html" rel="external">"Diagnosis of growth hormone deficiency in children", section on 'Testing for growth hormone deficiency'</a> and  <a class="medical medical_review" href="/d/html/6641.html" rel="external">"Growth hormone deficiency in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children</strong> – The optimal approach to dosing rhGH for PWS has not been fully established. Consensus guidelines suggest body surface area (BSA)-based dosing to avoid using excessive GH doses due to the high prevalence of obesity in PWS [<a href="#rid23">23</a>]. However, weight-based dosing is still very common.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>BSA-based dosing – Consensus guidelines suggest a starting rhGH dose of 0.5 mg/m<sup>2</sup>/day for infants and children based on BSA, with subsequent adjustments up to approximately 1 mg/m<sup>2</sup>/day as needed to achieve a target IGF-1 level in the upper part of the normal range for age (between +1 to +2 standard deviations for age) [<a href="#rid23">23</a>]. Some individuals with PWS (particularly infants) may require rhGH doses as high as 1.5 mg/m<sup>2</sup>/day. The child's BSA can be derived from a nomogram or calculator (<a class="calc calc_professional" href="/d/html/13406.html" rel="external">calculator 1</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Weight-based dosing – rhGH may be dosed based on body weight, with the recommended dose for infants and children of 0.034 mg/kg/day (0.24 mg/kg/week) [<a href="#rid65">65</a>], although some experts use as much as 0.05 mg/kg/day (0.35 mg/kg/week) [<a href="#rid66">66</a>]. The patient's actual body weight is used even if the patient has obesity. Many clinicians monitor IGF-1 and adjust doses accordingly [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent2">GH is given by subcutaneous injection. It is typically administered daily, although longer-acting formulations designed for weekly administration are now available for the treatment of GH deficiency. (See  <a class="medical medical_review" href="/d/html/5843.html" rel="external">"Treatment of growth hormone deficiency in children", section on 'Growth hormone treatment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adults</strong> – In adults with PWS, the starting dose for rhGH is 0.1 to 0.2 mg/day, which is the same starting dose as for adults with GH deficiency without PWS. The dose is then titrated to achieve a serum IGF-1 level between 0 and +2 standard deviations for age and sex [<a href="#rid23">23</a>]. The dosing may also be influenced by the presence of edema, prior rhGH treatment, sensitivity, and concomitant oral estrogen use. After dose titration, the dose for adults with GH deficiency (with or without PWS) is approximately 0.4 mg/day (typical range 0.2 mg to 1.0 mg). Relatively high doses are needed in younger individuals (in particular, young females) and lower doses in older individuals. (See  <a class="medical medical_review" href="/d/html/6641.html" rel="external">"Growth hormone deficiency in adults", section on 'Treatment protocol'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential benefits</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children</strong> – The efficacy of rhGH in children with PWS is supported by many observational studies and a few small randomized trials that consistently demonstrated improvements in linear growth, body composition/obesity, bone density, physical function, and motor development [<a href="#rid67">67-73</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Motor development – In a meta-analysis of five randomized trials involving 154 infants and children with PWS (age 1.3 to 3 years), those treated with rhGH scored higher on standardized tests of motor development (standard mean difference 0.71, 95% CI 0.38-1.03) [<a href="#rid73">73</a>]. In a representative trial that enrolled only infants and toddlers (29 participants age six months to three years), rhGH therapy improved motor development during the first year of treatment [<a href="#rid74">74</a>]. Standardized scores for motor development on the Bayley Scales of Infant Development (BSID) increased by an average of 11.2 percent in the rhGH group compared with a decrease of 18.5 percent in the control group.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cognitive development – In the trial of rhGH in infants and toddlers described above, rhGH therapy improved cognitive development during the first year of treatment [<a href="#rid74">74</a>]. Standardized BSID scores for mental development increased by an average of 9.3 percent in the rhGH group compared with a 2.9 percent decrease in the control group. In the meta-analysis described above, a separate analysis of six trials involving 165 infants, children, and adolescents with PWS found that cognitive scores were similar in rhGH-treated children and untreated controls (standard mean difference 0.2, 95% CI -0.1 to 0.5) [<a href="#rid73">73</a>]. However, two of the trials in this analysis enrolled children at an older age (the average age in one trial was seven years; in the other, it was 17 years). This may explain the lack of benefit on cognitive outcome in the pooled analysis.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Growth and body composition – Available studies have consistently shown that rhGH improves linear growth and body composition/obesity regardless of whether it is started in infancy or later in childhood [<a href="#rid72">72</a>]. In a meta-analysis of nine randomized trials (328 patients), rhGH improved height and body mass index (BMI) compared with controls (mean difference in Z-score for height 1.67 [95% CI 1.54-1.81]; mean difference in Z score for BMI -0.67 [95% CI -0.87 to -0.47]) [<a href="#rid72">72</a>]. Additional long-term data are needed to determine whether therapy with rhGH increases adult height. Treatment may also improve lipid profiles [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent3">Observational studies and clinical trials have reported similar benefits of rhGH in infants and young children [<a href="#rid70">70,71,76,77</a>]. In a randomized trial involving 22 participants ages 5 to 32 months, rhGH combined with physical therapy increased muscle thickness, which was related to muscle strength and motor performance compared with a control group given physical therapy alone [<a href="#rid70">70,71</a>]. In a third randomized trial (29 participants age 4 to 37 months), those treated with rhGH had greater mobility skill acquisition and improvement in body composition [<a href="#rid77">77</a>]. Initiating treatment before the age of 18 months was associated with accelerated acquisition of mobility skills compared with controls of the same age. These findings support our practice of initiating rhGH at the time of PWS diagnosis, and ideally prior to one year of age, consistent with expert consensus [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent3">The response to rhGH in children with PWS is greatest during the first 12 months of therapy [<a href="#rid78">78</a>]. Nevertheless, patients have had continued improvement in linear growth, bone density, and body composition when rhGH has been administered in sufficient doses for as long as five years [<a href="#rid79">79</a>]. However, even with long-term rhGH treatment, body composition is not completely normalized.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adults</strong> – Continuation or initiation of rhGH during adulthood has beneficial effects on body composition similar to those seen in adults without PWS who were treated for GH deficiency [<a href="#rid80">80-82</a>]. The evidence was outlined in a systematic review that included nine randomized trials and 20 observational studies [<a href="#rid81">81</a>]. Meta-analysis of the trial data was not possible, due to substantial heterogeneity in trial designs and outcomes measured. In the included trials that examined body composition outcomes at 12 months, all three reported reduced fat mass (range 2.9 to 4.2 kg) and increased lean body mass (range 1.5 to 2.3 kg). Similar findings were noted in the observational studies. BMI slightly decreased in two trials, although the difference was not statistically significant. There were no apparent differences in bone mineral density, low-density lipoprotein cholesterol, or cognition. A case series of adults with PWS undergoing long-term rhGH treatment (20 years) noted positive effects on body composition without any serious side effects [<a href="#rid83">83</a>]. A case series reported improvements in a standardized measure of quality of life during rhGH therapy [<a href="#rid84">84</a>]. GH replacement is not considered a weight loss medication.</p><p></p><p class="bulletIndent2">Additional support for the efficacy of rhGH in adult patients with PWS comes from the observation that discontinuation of rhGH treatment after epiphyseal closure leads to adverse changes in body composition [<a href="#rid85">85-88</a>]. Continuation or resumption of low-dose adult rhGH therapy does not have clinically important adverse effects on glucose homeostasis or cardiovascular risk markers [<a href="#rid81">81,89,90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Safety</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Respiratory complications – Limited evidence suggest a short-term risk for respiratory complications in a few patients after initiating rhGH treatment in children with PWS. As of 2006, there were reports of at least 20 fatalities worldwide coinciding with the use of exogenous rhGH treatment in children with PWS [<a href="#rid91">91,92</a>]. The deaths were associated with obesity and respiratory problems and/or were unexpected, and most occurred within the first three months of rhGH treatment. Whether the deaths were directly related to the use of rhGH therapy is unknown since children with PWS have an increased risk of sudden unexpected death independent of treatment with rhGH.</p><p></p><p class="bulletIndent2">The increased short-term risks for obstructive sleep apnea (OSA) during treatment with rhGH tend to occur in children with baseline obstructive symptoms or intercurrent upper respiratory tract infections [<a href="#rid93">93</a>]. No changes in sleep-disordered breathing were attributable to rhGH treatment. This was also seen in another study of 64 children with PWS 0 to 2.5 years old, in whom OSA appeared to develop independently of GH treatment [<a href="#rid94">94</a>]. Respiratory complications have not been reported in adults with PWS treated with rhGH [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent2">Because of these concerns, the US Food and Drug Administration has added labeling to rhGH products stating that rhGH therapy is contraindicated in patients with PWS who have severe obesity or severe respiratory impairment [<a href="#rid96">96-98</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Scoliosis – The risk of scoliosis generally increases with height velocity and might be increased in patients treated with rhGH. However, studies have suggested that rhGH therapy does not increase the risk or severity of scoliosis in patients with PWS and the presence of scoliosis is not a contraindication to rhGH therapy [<a href="#rid23">23,95,99</a>]. (See <a class="local">'Orthopedic problems'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment evaluation and monitoring</strong> – Patients with PWS should not begin rhGH therapy if any of the following are present [<a href="#rid23">23</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe obesity – eg, &gt;225 percent of ideal body weight in children or BMI &gt;40 kg/m<sup>2</sup> in adults with uncontrolled comorbidities</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute respiratory infection – Initiation of rhGH therapy should be delayed until the patient has fully recovered</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Uncontrolled severe OSA, diabetes, hypothyroidism, or adrenal insufficiency</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Active cancer or psychosis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe malnutrition – Delay initiation of rhGH until nutrition status is stabilized</p><p></p><p class="bulletIndent1">Accordingly, pretreatment evaluation and monitoring include [<a href="#rid23">23</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Respiratory</strong> – Prior to starting rhGH treatment, all children with PWS should undergo evaluation for upper airway obstruction, ideally with polysomnography or, at a minimum, sleep oximetry [<a href="#rid23">23</a>]. In those with severe OSA, rhGH treatment should not be initiated until the sleep-disordered breathing is effectively treated by weight loss in those with severe obesity and/or by adenotonsillectomy or other surgical intervention to treat the airway obstruction. Those with significant abnormalities on a polysomnogram should have follow-up studies approximately one month after beginning rhGH treatment.</p><p></p><p class="bulletIndent2">During rhGH treatment, patients should be clinically reevaluated if they develop intercurrent upper respiratory tract infections or increased obstructive symptoms. rhGH treatment should be interrupted if patients develop signs of upper respiratory obstruction (including onset of or increased snoring) and/or new onset of sleep apnea. Particular care should be taken in managing this issue in infants and toddlers, who appear to be at the highest risk for respiratory compromise because of underlying hypotonia. For these children, monitoring oxygen saturation during sleep for the first one to two months after starting rhGH treatment should be considered. The rhGH doses administered in adults with PWS are much lower than those in children with PWS, and rhGH treatment has not been associated with adverse severe respiratory outcomes or polysomnographic findings in adults [<a href="#rid23">23,75,100</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endocrine</strong> – For older children or adults with obesity, evaluate for type 2 diabetes mellitus prior to rhGH treatment and continue to monitor during therapy [<a href="#rid23">23</a>]. One of the physiologic effects of GH is induction of insulin resistance to varying degrees, so all patients should be monitored for development or progression of glucose intolerance during rhGH treatment. If rhGH therapy is undertaken in a patient with diabetes, glycemia should be well controlled prior to starting rhGH therapy and the patient should also be monitored for retinopathy and albuminuria.</p><p></p><p class="bulletIndent2">Therapy with rhGH in PWS does not have known effects on the underlying risk for hypothyroidism or adrenal insufficiency. Nonetheless, pretreatment testing and ongoing monitoring for hypothyroidism are suggested [<a href="#rid23">23</a>]. Pretreatment testing for adrenal insufficiency is not required when there are no clinical signs but should be done immediately if suggestive symptoms develop (unexplained nausea, vomiting, or hypotension, especially under physical stress conditions). (See <a class="local">'Hypothyroidism'</a> below and <a class="local">'Central adrenal insufficiency'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Orthopedic</strong> – Scoliosis is not a contraindication to rhGH therapy but should be monitored closely for signs of progression [<a href="#rid23">23</a>]. (See <a class="local">'Orthopedic problems'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neurologic</strong> – Evaluate for idiopathic intracranial hypertension (pseudotumor cerebri) if suspicious symptoms develop before or during rhGH therapy (headache, visual changes, nausea).</p><p></p><p class="headingAnchor" id="H3780961218"><span class="h2">Hypogonadism</span><span class="headingEndMark"> — </span>Hypogonadism is a nearly universal feature of PWS [<a href="#rid101">101</a>]. It can be of primary (peripheral) or secondary (hypothalamic) origin or a combination of these mechanisms. It is characterized by low levels of luteinizing hormone and inhibin B combined with high follicle-stimulating hormone [<a href="#rid101">101</a>].</p><p>Manifestations of hypogonadism are:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cryptorchidism</strong> – Approximately two-thirds of boys have cryptorchidism. Treatment of cryptorchidism with human chorionic gonadotropin (hCG) is sometimes effective, and a trial can be attempted in the hope of avoiding surgical treatment [<a href="#rid102">102</a>]. In one series of boys with PWS treated with hCG for six weeks, almost one-quarter of testes reached a stable scrotal position and thus did not require orchiopexy [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pubertal delay</strong> – Most children with PWS have pubertal delay. An expert panel has suggested annual monitoring of sex steroids and bone mineral density in adolescents and adults, with hormone replacement as indicated [<a href="#rid64">64</a>]. We suggest consultation with an endocrinologist to discuss initiating sex hormone therapy. After puberty, sex hormones are important for secondary sex characteristics, mood, bone mineral density, and body composition. Decisions about initiation and dosing of sex hormone therapy should include considerations about potential adverse effects of sex hormones on mood, behavior, and epiphyseal closure. (See  <a class="medical medical_review" href="/d/html/5814.html" rel="external">"Approach to the patient with delayed puberty"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fertility</strong> – Males with PWS are considered infertile, and there have been no known reports of PWS males fathering children. Females with PWS have markedly reduced fertility, with case reports describing a few pregnancies. If the mother's PWS is caused by uniparental disomy, there is substantial risk for Angelman syndrome in the offspring [<a href="#rid104">104</a>].</p><p></p><p class="headingAnchor" id="H934791837"><span class="h2">Low bone mineral density</span><span class="headingEndMark"> — </span>Dual-energy x-ray absorptiometry (DXA) scans should be obtained on all patients with PWS beginning at five years of age and every two to three years thereafter. These scans are useful in monitoring bone density as well as body composition. In addition, calcium and vitamin D intake should be reviewed through periodic dietary recalls and supplemented as necessary to meet daily recommended intakes for both of these nutrients. (See  <a class="medical medical_review" href="/d/html/5363.html" rel="external">"Measurement of body composition in children"</a> and  <a class="medical medical_review" href="/d/html/2046.html" rel="external">"Screening for osteoporosis in postmenopausal women and men", section on 'Bone mineral density'</a>.)</p><p>Patients with low bone density as determined by DXA scanning should have further evaluation for other causes of osteopenia, including inadequate intake of vitamin D and calcium, decreased physical activity, hypogonadism, GH deficiency, and hypothyroidism. Although bone density is improved by rhGH treatment, it often remains below that of children without PWS and may benefit from age-appropriate sex hormone replacement therapy [<a href="#rid16">16,105</a>]. In addition, adults with severe osteoporosis might need treatment with bone resorption inhibitors [<a href="#rid106">106</a>].</p><p class="headingAnchor" id="H1571459687"><span class="h2">Hypothyroidism</span><span class="headingEndMark"> — </span>Up to 17 percent of patients with PWS have central hypothyroidism, which may be congenital or can develop at any time after birth [<a href="#rid107">107-109</a>]. These observations could be confounded by the presence of obesity, which can cause a mild, reversible elevation of thyroid-stimulating hormone (TSH). As in the general population, primary hypothyroidism (peripheral thyroid dysfunction) may also occur in PWS.</p><p>Thyroid status should be evaluated in patients with PWS by measuring free thyroxine (fT4) and TSH. We suggest testing every few months during the first year of life, then annually thereafter. Testing for hypothyroidism is also appropriate in any child with growth failure or decreased bone density and in those in whom there is an inadequate response to rhGH therapy. Routine measurement of fT4 is important to detect central hypothyroidism. TSH levels are also helpful in diagnosing primary hypothyroidism, which is less common than central hypothyroidism in PWS patients.</p><p>Evaluation and management of hypothyroidism are discussed separately. (See  <a class="medical medical_review" href="/d/html/5836.html" rel="external">"Clinical features and detection of congenital hypothyroidism"</a> and  <a class="medical medical_review" href="/d/html/5837.html" rel="external">"Treatment and prognosis of congenital hypothyroidism"</a> and  <a class="medical medical_review" href="/d/html/5838.html" rel="external">"Acquired hypothyroidism in childhood and adolescence"</a> and  <a class="medical medical_review" href="/d/html/7849.html" rel="external">"Central hypothyroidism"</a>.)</p><p class="headingAnchor" id="H2174601404"><span class="h2">Central adrenal insufficiency</span><span class="headingEndMark"> — </span>Central adrenal insufficiency is not considered a part of PWS, but studies report conflicting results for cortisol response to testing [<a href="#rid53">53-55</a>]. In a study of 25 children and adolescents, 60 percent had a low response to a test of corticotropin (ACTH) secretory ability (<a class="drug drug_pediatric" data-topicid="12607" href="/d/drug information/12607.html" rel="external">metyrapone</a> test), suggesting that they might be at risk for acute adrenal insufficiency under stress conditions [<a href="#rid53">53</a>]. In a large case series of adults with PWS, fewer than 2 percent were diagnosed with central adrenal insufficiency, using either metyrapone or insulin-induced hypoglycemia testing [<a href="#rid110">110</a>]. Whether subclinical adrenal dysfunction is responsible for some of the unexplained deaths observed in patients with PWS remains to be determined.</p><p>However, because PWS is a hypothalamic disease, there is at least a theoretical risk for an association with central adrenal insufficiency. In our practice, we screen for adrenal insufficiency if there are clinical symptoms suggesting the possibility of adrenal insufficiency (unexplained nausea, vomiting, or hypotension, especially under physical stress conditions). We screen by measuring 8 AM cortisol and proceed to ACTH stimulation testing if the cortisol result is abnormal or if there is a high level of suspicion. (See  <a class="medical medical_review" href="/d/html/5828.html" rel="external">"Clinical manifestations and diagnosis of adrenal insufficiency in children", section on 'Initial evaluation'</a>.)</p><p class="headingAnchor" id="H4090252002"><span class="h1">TYPE 2 DIABETES MELLITUS</span><span class="headingEndMark"> — </span>Individuals with PWS who have obesity (body mass index [BMI] ≥95<sup>th</sup> percentile for children and BMI ≥30 kg/m<sup>2</sup> for adults) should be screened annually for type 2 diabetes mellitus by measuring fasting blood glucose and hemoglobin A1c (A1C) and/or performing an oral glucose tolerance test [<a href="#rid111">111</a>]. (See  <a class="medical medical_review" href="/d/html/5820.html" rel="external">"Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/5869.html" rel="external">"Overview of the health consequences of obesity in children and adolescents", section on 'Type 2 diabetes mellitus'</a> and  <a class="medical medical_review" href="/d/html/5370.html" rel="external">"Overweight and obesity in adults: Health consequences"</a>.)</p><p>The reported prevalence of type 2 diabetes mellitus in adults with PWS is between 9 and 22 percent, with generally higher percentages in those with obesity and those living in less structured environments without nutrition supervision and exercise programs. Patients with PWS diagnosed with type 2 diabetes mellitus should be treated according to general guidelines. Glucagon-like peptide 1 receptor agonists (GLP-1 RA) may be a valuable therapeutic option because of their beneficial effects on body weight, although their effects are not well studied in patients with PWS. These drugs should be approached with extreme caution among those with history of slow gastric emptying, vomiting, or gastric dilation. (See <a class="local">'Other interventions for obesity'</a> above and  <a class="medical medical_review" href="/d/html/5821.html" rel="external">"Management of type 2 diabetes mellitus in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus"</a>.)</p><p>Further, the risk of glucose intolerance and type 2 diabetes mellitus is increased if a patient with obesity is taking growth hormone (GH) therapy, which can exacerbate insulin resistance.</p><p class="headingAnchor" id="H106781663"><span class="h1">OTHER OBESITY-RELATED COMORBIDITIES</span><span class="headingEndMark"> — </span>Other obesity-related problems frequently seen in patients with PWS include dyslipidemia, cholelithiasis, gastroesophageal reflux, nonalcoholic fatty liver disease, and, in children, idiopathic intracranial hypertension [<a href="#rid112">112</a>]. These comorbidities are generally treated as they would be in patients with obesity who do not have PWS. (See  <a class="medical medical_review" href="/d/html/5869.html" rel="external">"Overview of the health consequences of obesity in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/5370.html" rel="external">"Overweight and obesity in adults: Health consequences"</a>.)</p><p class="headingAnchor" id="H3782898166"><span class="h1">SLEEP AND RESPIRATORY DISORDERS</span><span class="headingEndMark"> — </span>Patients with PWS are at high risk for several types of sleep disorders [<a href="#rid113">113,114</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obstructive sleep apnea (OSA)</strong> – Sleep-disordered breathing occurs in at least 70 percent of children and young adults with PWS [<a href="#rid115">115,116</a>] and is associated with increased daytime sleepiness and behavioral disturbances. Clinicians should monitor all patients for sleep-related symptoms, including consistent snoring, pauses in breathing for longer than five seconds, or daytime sleepiness, particularly during intercurrent respiratory illnesses. Patients with severe obesity or any clinical symptoms of sleep apnea should be referred for a polysomnogram (sleep study), if possible, and evaluated for adenotonsillar hypertrophy.</p><p></p><p class="bulletIndent1">Tonsillectomy, adenoidectomy, or tracheostomy placement may be required in patients with severe OSA. Patients with PWS who undergo adenotonsillectomy are at increased risk for postoperative complications, including respiratory complications during the perioperative period and velopharyngeal insufficiency [<a href="#rid117">117-119</a>]. Detailed preoperative assessment and close postoperative monitoring are essential. OSA often improves after adenotonsillectomy but may not resolve or may recur, so it is important to follow patients postoperatively with polysomnography [<a href="#rid120">120,121</a>]. Although one series of PWS patients undergoing bariatric surgery reported complete amelioration of symptoms of sleep-disordered breathing after weight loss, these results should be interpreted with caution because factors other than obesity contribute to OSA in individuals with PWS [<a href="#rid27">27,122</a>]. Continuous positive airway pressure treatment may also be indicated but is often not well tolerated or accepted by the patient. Working with a psychologist may help with mask adherence. Patients with severe OSA should be evaluated for cor pulmonale. (See  <a class="medical medical_review" href="/d/html/6363.html" rel="external">"Evaluation of suspected obstructive sleep apnea in children"</a> and  <a class="medical medical_review" href="/d/html/6373.html" rel="external">"Management of obstructive sleep apnea in children"</a> and  <a class="medical medical_review" href="/d/html/7695.html" rel="external">"Obstructive sleep apnea: Overview of management in adults"</a>.)</p><p></p><p class="bulletIndent1">A possible interaction between OSA and <a class="drug drug_pediatric" data-topicid="13354" href="/d/drug information/13354.html" rel="external">recombinant human growth hormone</a> (rhGH) treatment is discussed above. (See <a class="local">'Recombinant growth hormone treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Excessive daytime sleepiness</strong> – Excessive daytime sleepiness is present in most individuals with PWS [<a href="#rid123">123</a>] and is probably due to a combination of OSA and a primary disorder of vigilance [<a href="#rid124">124,125</a>]. The polysomnographic features resemble narcolepsy, but clinical symptoms of cataplexy and sleep paralysis that are typical of narcolepsy are uncommon in individuals with PWS [<a href="#rid114">114,126</a>]. The excessive daytime sleepiness does not consistently respond to interventions for OSA. <a class="drug drug_pediatric" data-topicid="13066" href="/d/drug information/13066.html" rel="external">Modafinil</a> may have some benefits for daytime sleepiness in these patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insomnia</strong> – Paradoxically, patients with PWS are also at risk for chronic insomnia [<a href="#rid114">114,127</a>].</p><p></p><p class="headingAnchor" id="H2482649392"><span class="h1">ORTHOPEDIC PROBLEMS</span><span class="headingEndMark"> — </span>Scoliosis is common in PWS. Scoliosis with a Cobb angle &gt;10° affects up to 80 percent of patients, 20 to 40 percent of patients have clinically significant scoliosis, and 13 percent of patients require brace treatment or surgery [<a href="#rid128">128</a>]. Approximately 30 percent of infants and children are affected, and the prevalence increases with age [<a href="#rid128">128</a>]. In patients with obesity, it may be difficult to detect scoliosis with a physical examination, so radiographic evaluation is recommended. In our practice, we monitor for scoliosis with a clinical examination until early school age (approximately age six years), then initiate monitoring with spine radiographs every one to two years thereafter until growth is complete.</p><p>The presence of scoliosis is not a contraindication to <a class="drug drug_pediatric" data-topicid="13354" href="/d/drug information/13354.html" rel="external">recombinant human growth hormone</a> (rhGH) therapy (see <a class="local">'Recombinant growth hormone treatment'</a> above). Serial spinal casting has been used for infants and may avoid or delay the need for surgery [<a href="#rid129">129</a>]. Several case series have reported unusually high complication rates for scoliosis surgery in individuals with PWS [<a href="#rid130">130,131</a>]. The largest series described outcomes of scoliosis surgery among 16 patients with PWS [<a href="#rid130">130</a>]. Nine of these patients experienced severe complications, four of which were the development of severe progressive cervical-thoracic kyphosis above the fusion requiring reoperation and three of these were further complicated by spinal cord injury.</p><p>Patients with PWS are also at increased risk for hip dysplasia and lower limb alignment abnormalities [<a href="#rid132">132,133</a>]. Protocols for radiographic monitoring have been suggested but not widely implemented [<a href="#rid132">132</a>]. Unlike other children with obesity, they do not appear to have increased risk for slipped capital femoral epiphysis [<a href="#rid134">134</a>].</p><p class="headingAnchor" id="H16690561"><span class="h1">RESOURCES AND INFORMATION</span><span class="headingEndMark"> — </span>The following organizations provide information and support for families affected by PWS, including detailed medical information about PWS and crisis support for families and clinicians:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.pwsausa.org%2F&amp;token=%2FydOckGcXt0QpwouWndQAWNsLHUsvv4AusVw0LAA1pSvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=5864" target="_blank">Prader-Willi Syndrome Association USA</a> – Phone (941)-312-0400</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fipwso.org%2F&amp;token=cS565BFoM5u6cTjHVZIVCD8Gtp31zeQMzB64H13cQCU%3D&amp;TOPIC_ID=5864" target="_blank">International Prader-Willi Syndrome Organisation</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fpwr.org%2F&amp;token=DzPMsBhauzgvZzN%2FvOiltS5DQrkM14VR37rB0UTQEyw%3D&amp;TOPIC_ID=5864" target="_blank">Foundation for Prader-Willi Research</a></p><p></p><p class="headingAnchor" id="H1435549464"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111346.html" rel="external">"Society guideline links: Obesity in children"</a> and  <a class="medical medical_society_guidelines" href="/d/html/114455.html" rel="external">"Society guideline links: Growth hormone deficiency and other growth disorders"</a>.)</p><p class="headingAnchor" id="H35"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General approach</strong> – Prader-Willi syndrome (PWS) is a multisymptomatic disease and must be understood as a whole for treatment and management to be effective. Most patients with PWS have difficulties communicating how they feel as well as their medical needs, and they might understate or exaggerate their symptoms. Management of feeding, obesity, and comorbidities is summarized in the table  (<a class="graphic graphic_table graphicRef140076" href="/d/graphic/140076.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of feeding and obesity</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A secured food environment and restriction of food intake are critical parts of care for patients with PWS, together with regular physical activity. Patients tend to do best in a highly structured living environment in which access to food is strictly limited through close supervision and physical barriers. Food security practices should also be employed in the school and work setting, requiring continuing education of teachers and supervisors. (See <a class="local">'Feeding and obesity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No pharmacologic agent has been shown to be consistently helpful in controlling appetite or binge eating. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are established treatments for adolescent and adult patients with obesity (without PWS) and particularly those with type 2 diabetes mellitus. In patients with PWS, they may have some effects on body weight and hyperphagia, based on limited data, but should be approached with extreme caution among those with history of slow gastric emptying, vomiting, or gastric dilation. Weight loss surgery for patients with PWS has been reported but not well studied. There are concerns about both efficacy and safety of the procedure in PWS patients. (See <a class="local">'Other interventions for obesity'</a> above and  <a class="medical medical_review" href="/d/html/1772.html" rel="external">"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute severe complications of hyperphagia include choking episodes and acute abdominal distension, both of which can be life-threatening. (See <a class="local">'Acute complications of hyperphagia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endocrine abnormalities</strong> – Individuals with PWS have increased risk for growth hormone (GH) deficiency, hypogonadism, type 2 diabetes mellitus, low bone mineral density, and central hypothyroidism and should have routine monitoring for these disorders. (See <a class="local">'Hypothalamic and pituitary dysfunction'</a> above and <a class="local">'Type 2 diabetes mellitus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recombinant human growth hormone</strong><strong> (rhGH) therapy</strong> – We recommend treatment with rhGH for all children with PWS (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>); we also suggest rhGH for most adults with PWS (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). In children, rhGH improves linear growth, body composition, and neuromotor development. In adults, continuing or initiating rhGH has benefits on body composition, physical performance, and quality of life. rhGH treatment of children with PWS has significantly changed the clinical characteristics of the syndrome.</p><p></p><p class="bulletIndent1">In general, rhGH is a safe therapy. Contraindications to initiating rhGH therapy at any age include severe obesity, untreated severe obstructive sleep apnea (OSA), acute respiratory infection, and uncontrolled diabetes. Patients should be evaluated for these prior to starting treatment and should be monitored during treatment for development of respiratory obstruction and/or endocrine abnormalities, in particular type 2 diabetes mellitus. (See <a class="local">'Recombinant growth hormone treatment'</a> above.)</p><p></p><p class="bulletIndent1">Treatment with rhGH is optimally initiated before one year of age because of benefits on early motor and cognitive development; however, cost and insurance constraints may limit the feasibility of early initiation in some countries. If treatment cannot be started early, it should be started as soon as the child has evidence of growth failure. (See <a class="local">'Recombinant growth hormone treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sleep disorders</strong> – PWS is associated with increased risks for OSA, excessive daytime sleepiness (similar to narcolepsy), and insomnia. Management includes routine monitoring and surgical or medical intervention as indicated. (See <a class="local">'Sleep and respiratory disorders'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Management of Prader-Willi Syndrome, Butler M, Lee PDK, Whitman BY (Eds), Springer-Verlag, New York 2006.</li><li><a class="nounderline abstract_t">Alsaif M, Elliot SA, MacKenzie ML, et al. Energy Metabolism Profile in Individuals with Prader-Willi Syndrome and Implications for Clinical Management: A Systematic Review. Adv Nutr 2017; 8:905.</a></li><li class="breakAll">Gourash LM, Forster JL. Pittsburgh Partnership. Regulation of Weight in Prader‐Willi Syndrome: Theoretical and Practical Considerations. 2009. Available at: https://pittsburghpartnership.com/handouts/Weight%20Regulation%20in%20PWS.pdf (Accessed on October 05, 2022).</li><li><a class="nounderline abstract_t">Kayadjanian N, Vrana-Diaz C, Bohonowych J, et al. Characteristics and relationship between hyperphagia, anxiety, behavioral challenges and caregiver burden in Prader-Willi syndrome. PLoS One 2021; 16:e0248739.</a></li><li><a class="nounderline abstract_t">Crinò A, Fintini D, Bocchini S, Grugni G. Obesity management in Prader-Willi syndrome: current perspectives. Diabetes Metab Syndr Obes 2018; 11:579.</a></li><li><a class="nounderline abstract_t">Ng NBH, Low YW, Rajgor DD, et al. The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review. Clin Endocrinol (Oxf) 2022; 96:144.</a></li><li><a class="nounderline abstract_t">Diene G, Angulo M, Hale PM, et al. Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity. J Clin Endocrinol Metab 2022; 108:4.</a></li><li><a class="nounderline abstract_t">Sani E, Prato GD, Zenti MG, et al. Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Willi Syndrome: A Case Report. Endocr Metab Immune Disord Drug Targets 2022; 22:1053.</a></li><li><a class="nounderline abstract_t">Dykens EM, Miller J, Angulo M, et al. Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome. JCI Insight 2018; 3.</a></li><li><a class="nounderline abstract_t">Ryman D, Deal CL. Topline Results of the CARE-PWS Phase 3 Study: Intranasal Carbetocin Improves Hyperphagia and Anxiety and Distress Symptoms in Prader-Willi Syndrome (PWS). Journal of Clinical Endocrinology and Metabolism 2021; 105 Suppl 1:A689.</a></li><li><a class="nounderline abstract_t">Einfeld SL, Smith E, McGregor IS, et al. A double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome. Am J Med Genet A 2014; 164A:2232.</a></li><li><a class="nounderline abstract_t">Tauber M, Boulanouar K, Diene G, et al. The Use of Oxytocin to Improve Feeding and Social Skills in Infants With Prader-Willi Syndrome. Pediatrics 2017; 139.</a></li><li><a class="nounderline abstract_t">Althammer F, Muscatelli F, Grinevich V, Schaaf CP. Oxytocin-based therapies for treatment of Prader-Willi and Schaaf-Yang syndromes: evidence, disappointments, and future research strategies. Transl Psychiatry 2022; 12:318.</a></li><li class="breakAll">US National Library of Medicine, Clinical Trials database. Available at: https://www.clinicaltrials.gov/ct2/results?cond=Prader-Willi+Syndrome (Accessed on January 25, 2022).</li><li><a class="nounderline abstract_t">Poitou C, Mosbah H, Clément K. MECHANISMS IN ENDOCRINOLOGY: Update on treatments for patients with genetic obesity. Eur J Endocrinol 2020; 183:R149.</a></li><li><a class="nounderline abstract_t">Tauber M, Hoybye C. Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction. Lancet Diabetes Endocrinol 2021; 9:235.</a></li><li><a class="nounderline abstract_t">Shapira NA, Lessig MC, Lewis MH, et al. Effects of topiramate in adults with Prader-Willi syndrome. Am J Ment Retard 2004; 109:301.</a></li><li><a class="nounderline abstract_t">Bonnot O, Cohen D, Thuilleaux D, et al. Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature. Eur J Pediatr 2016; 175:9.</a></li><li><a class="nounderline abstract_t">Consoli A, Çabal Berthoumieu S, Raffin M, et al. Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study. Transl Psychiatry 2019; 9:274.</a></li><li><a class="nounderline abstract_t">Haqq AM, Stadler DD, Rosenfeld RG, et al. Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader-Willi syndrome. J Clin Endocrinol Metab 2003; 88:3573.</a></li><li><a class="nounderline abstract_t">Tan TM, Vanderpump M, Khoo B, et al. Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome. J Clin Endocrinol Metab 2004; 89:4162.</a></li><li><a class="nounderline abstract_t">De Waele K, Ishkanian SL, Bogarin R, et al. Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome. Eur J Endocrinol 2008; 159:381.</a></li><li><a class="nounderline abstract_t">Deal CL, Tony M, Höybye C, et al. GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab 2013; 98:E1072.</a></li><li><a class="nounderline abstract_t">McCandless SE, Yanovski JA, Miller J, et al. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2017; 19:1751.</a></li><li><a class="nounderline abstract_t">Gantz MG, Driscoll DJ, Miller JL, et al. Critical review of bariatric surgical outcomes in patients with Prader-Willi syndrome and other hyperphagic disorders. Obesity (Silver Spring) 2022; 30:973.</a></li><li><a class="nounderline abstract_t">Liu SY, Wong SK, Lam CC, Ng EK. Bariatric surgery for Prader-Willi syndrome was ineffective in producing sustainable weight loss: Long term results for up to 10 years. Pediatr Obes 2020; 15:e12575.</a></li><li><a class="nounderline abstract_t">Alqahtani AR, Elahmedi MO, Al Qahtani AR, et al. Laparoscopic sleeve gastrectomy in children and adolescents with Prader-Willi syndrome: a matched-control study. Surg Obes Relat Dis 2016; 12:100.</a></li><li><a class="nounderline abstract_t">Hu S, Huang B, Loi K, et al. Patients with Prader-Willi Syndrome (PWS) Underwent Bariatric Surgery Benefit more from High-Intensity Home Care. Obes Surg 2022; 32:1631.</a></li><li><a class="nounderline abstract_t">Scheimann AO, Butler MG, Gourash L, et al. Critical analysis of bariatric procedures in Prader-Willi syndrome. J Pediatr Gastroenterol Nutr 2008; 46:80.</a></li><li><a class="nounderline abstract_t">Chelala E, Cadiére GB, Favretti F, et al. Conversions and complications in 185 laparoscopic adjustable silicone gastric banding cases. Surg Endosc 1997; 11:268.</a></li><li><a class="nounderline abstract_t">De Peppo F, Di Giorgio G, Germani M, et al. BioEnterics intragastric balloon for treatment of morbid obesity in Prader-Willi syndrome: specific risks and benefits. Obes Surg 2008; 18:1443.</a></li><li><a class="nounderline abstract_t">Stevenson DA, Heinemann J, Angulo M, et al. Deaths due to choking in Prader-Willi syndrome. Am J Med Genet A 2007; 143A:484.</a></li><li><a class="nounderline abstract_t">Bellis SA, Kuhn I, Adams S, et al. The consequences of hyperphagia in people with Prader-Willi Syndrome: A systematic review of studies of morbidity and mortality. Eur J Med Genet 2022; 65:104379.</a></li><li><a class="nounderline abstract_t">Wharton RH, Wang T, Graeme-Cook F, et al. Acute idiopathic gastric dilation with gastric necrosis in individuals with Prader-Willi syndrome. Am J Med Genet 1997; 73:437.</a></li><li><a class="nounderline abstract_t">Stevenson DA, Heinemann J, Angulo M, et al. Gastric rupture and necrosis in Prader-Willi syndrome. J Pediatr Gastroenterol Nutr 2007; 45:272.</a></li><li><a class="nounderline abstract_t">Butler MG, Manzardo AM, Heinemann J, et al. Causes of death in Prader-Willi syndrome: Prader-Willi Syndrome Association (USA) 40-year mortality survey. Genet Med 2017; 19:635.</a></li><li><a class="nounderline abstract_t">Ma Y, Wu T, Liu Y, et al. Nutritional and metabolic findings in patients with Prader-Willi syndrome diagnosed in early infancy. J Pediatr Endocrinol Metab 2012; 25:1103.</a></li><li><a class="nounderline abstract_t">Schwartz L, Caixàs A, Dimitropoulos A, et al. Behavioral features in Prader-Willi syndrome (PWS): consensus paper from the International PWS Clinical Trial Consortium. J Neurodev Disord 2021; 13:25.</a></li><li><a class="nounderline abstract_t">Bennett JA, Germani T, Haqq AM, Zwaigenbaum L. Autism spectrum disorder in Prader-Willi syndrome: A systematic review. Am J Med Genet A 2015; 167A:2936.</a></li><li><a class="nounderline abstract_t">Schaaf CP, Gonzalez-Garay ML, Xia F, et al. Truncating mutations of MAGEL2 cause Prader-Willi phenotypes and autism. Nat Genet 2013; 45:1405.</a></li><li><a class="nounderline abstract_t">Milner KM, Craig EE, Thompson RJ, et al. Prader-Willi syndrome: intellectual abilities and behavioural features by genetic subtype. J Child Psychol Psychiatry 2005; 46:1089.</a></li><li><a class="nounderline abstract_t">Dykens EM, Roof E. Behavior in Prader-Willi syndrome: relationship to genetic subtypes and age. J Child Psychol Psychiatry 2008; 49:1001.</a></li><li><a class="nounderline abstract_t">Miller JL, Angulo M. An open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndrome. Am J Med Genet A 2014; 164A:421.</a></li><li><a class="nounderline abstract_t">Singh D, Wakimoto Y, Filangieri C, et al. Guanfacine Extended Release for the Reduction of Aggression, Attention-Deficit/Hyperactivity Disorder Symptoms, and Self-Injurious Behavior in Prader-Willi Syndrome-A Retrospective Cohort Study. J Child Adolesc Psychopharmacol 2019; 29:313.</a></li><li><a class="nounderline abstract_t">Salehi P, Lee D, Ambartsumyan L, et al. Rectal Picking Masquerading as Inflammatory Bowel Disease in Prader-Willi Syndrome. J Pediatr Gastroenterol Nutr 2018; 67:59.</a></li><li class="breakAll">Whitman BY. Neurodevelopmental and neuropsychological aspects of Prader-Willi syndrome. In: Management of Prader-Willi Syndrome, 3rd ed, Butler M, Lee PDK, Whitman BY (Eds), Springer-Verlag, New York 2006. p.264.</li><li><a class="nounderline abstract_t">Sinnema M, Boer H, Collin P, et al. Psychiatric illness in a cohort of adults with Prader-Willi syndrome. Res Dev Disabil 2011; 32:1729.</a></li><li><a class="nounderline abstract_t">Whittington J, Holland A, Webb T, et al. Cognitive abilities and genotype in a population-based sample of people with Prader-Willi syndrome. J Intellect Disabil Res 2004; 48:172.</a></li><li><a class="nounderline abstract_t">Curfs LM, Fryns JP. Prader-Willi syndrome: a review with special attention to the cognitive and behavioral profile. Birth Defects Orig Artic Ser 1992; 28:99.</a></li><li><a class="nounderline abstract_t">Azor AM, Cole JH, Holland AJ, et al. Increased brain age in adults with Prader-Willi syndrome. Neuroimage Clin 2019; 21:101664.</a></li><li><a class="nounderline abstract_t">Pellikaan K, Ben Brahim Y, Rosenberg AGW, et al. Hypogonadism in Women with Prader-Willi Syndrome-Clinical Recommendations Based on a Dutch Cohort Study, Review of the Literature and an International Expert Panel Discussion. J Clin Med 2021; 10.</a></li><li><a class="nounderline abstract_t">Pellikaan K, Ben Brahim Y, Rosenberg AGW, et al. Hypogonadism in Adult Males with Prader-Willi Syndrome-Clinical Recommendations Based on a Dutch Cohort Study, Review of the Literature and an International Expert Panel Discussion. J Clin Med 2021; 10.</a></li><li><a class="nounderline abstract_t">de Lind van Wijngaarden RF, Otten BJ, Festen DA, et al. High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome. J Clin Endocrinol Metab 2008; 93:1649.</a></li><li><a class="nounderline abstract_t">Farholt S, Sode-Carlsen R, Christiansen JS, et al. Normal cortisol response to high-dose synacthen and insulin tolerance test in children and adults with Prader-Willi syndrome. J Clin Endocrinol Metab 2011; 96:E173.</a></li><li><a class="nounderline abstract_t">Obrynba KS, Hoffman RP, Repaske DR, et al. No central adrenal insufficiency found in patients with Prader-Willi syndrome with an overnight metyrapone test. J Pediatr Endocrinol Metab 2018; 31:809.</a></li><li><a class="nounderline abstract_t">Swaab DF, Purba JS, Hofman MA. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J Clin Endocrinol Metab 1995; 80:573.</a></li><li><a class="nounderline abstract_t">Paepegaey AC, Coupaye M, Jaziri A, et al. Impact of transitional care on endocrine and anthropometric parameters in Prader-Willi syndrome. Endocr Connect 2018; 7:663.</a></li><li><a class="nounderline abstract_t">Diene G, Mimoun E, Feigerlova E, et al. Endocrine disorders in children with Prader-Willi syndrome--data from 142 children of the French database. Horm Res Paediatr 2010; 74:121.</a></li><li><a class="nounderline abstract_t">Höybye C, Holland AJ, Driscoll DJ, Clinical and Scientific Advisory Board of The International Prader-Willi Syndrome Organisation. Time for a general approval of growth hormone treatment in adults with Prader-Willi syndrome. Orphanet J Rare Dis 2021; 16:69.</a></li><li><a class="nounderline abstract_t">Butler MG, Lee J, Cox DM, et al. Growth Charts for Prader-Willi Syndrome During Growth Hormone Treatment. Clin Pediatr (Phila) 2016; 55:957.</a></li><li><a class="nounderline abstract_t">Butler MG, Sturich J, Lee J, et al. Growth standards of infants with Prader-Willi syndrome. Pediatrics 2011; 127:687.</a></li><li><a class="nounderline abstract_t">Butler MG, Lee J, Manzardo AM, et al. Growth charts for non-growth hormone treated Prader-Willi syndrome. Pediatrics 2015; 135:e126.</a></li><li><a class="nounderline abstract_t">Duis J, van Wattum PJ, Scheimann A, et al. A multidisciplinary approach to the clinical management of Prader-Willi syndrome. Mol Genet Genomic Med 2019; 7:e514.</a></li><li><a class="nounderline abstract_t">Goldstone AP, Holland AJ, Hauffa BP, et al. Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab 2008; 93:4183.</a></li><li class="breakAll">Genotropin prescribing information (Pfizer pharmaceuticals, Inc). Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=577 (Accessed on June 16, 2013).</li><li class="breakAll">Carrel AL, Lee PDK, Mogul HR. Growth hormone and Prader-Willi syndrome. In: Management of Prader-Willi syndrome, 3rd ed, Butler MG, Lee PDK, Whitman BY (Eds), Springer Science, 2006. p.201.</li><li><a class="nounderline abstract_t">Bakker NE, Kuppens RJ, Siemensma EP, et al. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects. J Clin Endocrinol Metab 2013; 98:4013.</a></li><li><a class="nounderline abstract_t">Bakker NE, Lindberg A, Heissler J, et al. Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database. J Clin Endocrinol Metab 2017; 102:1702.</a></li><li><a class="nounderline abstract_t">Takeda A, Cooper K, Bird A, et al. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess 2010; 14:1.</a></li><li><a class="nounderline abstract_t">Reus L, Pillen S, Pelzer BJ, et al. Growth hormone therapy, muscle thickness, and motor development in Prader-Willi syndrome: an RCT. Pediatrics 2014; 134:e1619.</a></li><li><a class="nounderline abstract_t">Reus L, Pelzer BJ, Otten BJ, et al. Growth hormone combined with child-specific motor training improves motor development in infants with Prader-Willi syndrome: a randomized controlled trial. Res Dev Disabil 2013; 34:3092.</a></li><li><a class="nounderline abstract_t">Passone CGB, Franco RR, Ito SS, et al. Growth hormone treatment in Prader-Willi syndrome patients: systematic review and meta-analysis. BMJ Paediatr Open 2020; 4:e000630.</a></li><li><a class="nounderline abstract_t">Luo Y, Zheng Z, Yang Y, et al. Effects of growth hormone on cognitive, motor, and behavioral development in Prader-Willi syndrome children: a meta-analysis of randomized controlled trials. Endocrine 2021; 71:321.</a></li><li><a class="nounderline abstract_t">Festen DA, Wevers M, Lindgren AC, et al. Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome. Clin Endocrinol (Oxf) 2008; 68:919.</a></li><li><a class="nounderline abstract_t">Carrel AL, Myers SE, Whitman BY, et al. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with prader-willi syndrome. J Clin Endocrinol Metab 2010; 95:1131.</a></li><li><a class="nounderline abstract_t">Eiholzer U, L'allemand D, Schlumpf M, et al. Growth hormone and body composition in children younger than 2 years with Prader-Willi syndrome. J Pediatr 2004; 144:753.</a></li><li><a class="nounderline abstract_t">Carrel AL, Moerchen V, Myers SE, et al. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J Pediatr 2004; 145:744.</a></li><li><a class="nounderline abstract_t">Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab 2002; 87:1581.</a></li><li><a class="nounderline abstract_t">Obata K, Sakazume S, Yoshino A, et al. Effects of 5 years growth hormone treatment in patients with Prader-Willi syndrome. J Pediatr Endocrinol Metab 2003; 16:155.</a></li><li><a class="nounderline abstract_t">van der Klaauw AA, Romijn JA, Biermasz NR, et al. Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. Eur J Endocrinol 2006; 155:701.</a></li><li><a class="nounderline abstract_t">Rosenberg AGW, Passone CGB, Pellikaan K, et al. Growth Hormone Treatment for Adults With Prader-Willi Syndrome: A Meta-Analysis. J Clin Endocrinol Metab 2021; 106:3068.</a></li><li><a class="nounderline abstract_t">Damen L, Donze SH, Kuppens RJ, et al. Three years of growth hormone treatment in young adults with Prader-Willi syndrome: sustained positive effects on body composition. Orphanet J Rare Dis 2020; 15:163.</a></li><li><a class="nounderline abstract_t">Sjöström A, Höybye C. Twenty Years of GH Treatment in Adults with Prader-Willi Syndrome. J Clin Med 2021; 10.</a></li><li><a class="nounderline abstract_t">Bertella L, Mori I, Grugni G, et al. Quality of life and psychological well-being in GH-treated, adult PWS patients: a longitudinal study. J Intellect Disabil Res 2007; 51:302.</a></li><li><a class="nounderline abstract_t">Kuppens RJ, Bakker NE, Siemensma EP, et al. Beneficial Effects of GH in Young Adults With Prader-Willi Syndrome: A 2-Year Crossover Trial. J Clin Endocrinol Metab 2016; 101:4110.</a></li><li><a class="nounderline abstract_t">Koizumi M, Ida S, Shoji Y, et al. Visceral adipose tissue increases shortly after the cessation of GH therapy in adults with Prader-Willi syndrome. Endocr J 2018; 65:1127.</a></li><li><a class="nounderline abstract_t">Oto Y, Tanaka Y, Abe Y, et al. Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader-Willi syndrome. Am J Med Genet A 2014; 164A:671.</a></li><li><a class="nounderline abstract_t">Butler MG, Smith BK, Lee J, et al. Effects of growth hormone treatment in adults with Prader-Willi syndrome. Growth Horm IGF Res 2013; 23:81.</a></li><li><a class="nounderline abstract_t">Damen L, Grootjen LN, Donze SH, et al. Three years of growth hormone treatment in young adults with Prader-Willi Syndrome previously treated with growth hormone in childhood: Effects on glucose homeostasis and metabolic syndrome. Clin Endocrinol (Oxf) 2020; 93:439.</a></li><li><a class="nounderline abstract_t">Kuppens RJ, Bakker NE, Siemensma EP, et al. Metabolic health profile in young adults with Prader-Willi syndrome: results of a 2-year randomized, placebo-controlled, crossover GH trial. Clin Endocrinol (Oxf) 2017; 86:297.</a></li><li class="breakAll">US Food and Drug Administration. 2003 Safety Alert: Genotropin (somatropin [rDNA origin]) for injection). Available at: www.fda.gov/medwatch/SAFETY/2003/genotropin.htm (Accessed on August 05, 2006).</li><li class="breakAll">Lee PDK. Growth hormone and mortality in Prader-Willi syndrome. Growth, Genetics and Hormones journal. Available at: http://www.gghjournal.com/volume22/2/featureArticle.cfm (Accessed on March 27, 2013).</li><li><a class="nounderline abstract_t">Miller JL, Shuster J, Theriaque D, et al. Sleep disordered breathing in infants with Prader-Willi syndrome during the first 6 weeks of growth hormone therapy: a pilot study. J Clin Sleep Med 2009; 5:448.</a></li><li><a class="nounderline abstract_t">Zimmermann M, Laemmer C, Woelfle J, et al. Sleep-Disordered Breathing in Children with Prader-Willi Syndrome in Relation to Growth Hormone Therapy Onset. Horm Res Paediatr 2020; 93:85.</a></li><li><a class="nounderline abstract_t">de Lind van Wijngaarden RF, de Klerk LW, Festen DA, et al. Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome. J Clin Endocrinol Metab 2009; 94:1274.</a></li><li class="breakAll">Humatrope® Somatropin (rDNA origin) for injection vials and cartridges for use with the HumatroPen™ injection device. Eli Lilly and Company, Indianapolis, March 2004.</li><li class="breakAll">Nutropin Depot® [somatropin (rDNA origin) for injectable suspension]. Genentech, Inc. San Francisco, October 2004.</li><li class="breakAll">US Food and Drug Administration. Detailed view: Safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). Available at: www.fda.gov/medwatch/SAFETY/2004/sep04.htm (Accessed on January 18, 2006).</li><li><a class="nounderline abstract_t">Nagai T, Obata K, Ogata T, et al. Growth hormone therapy and scoliosis in patients with Prader-Willi syndrome. Am J Med Genet A 2006; 140:1623.</a></li><li><a class="nounderline abstract_t">Shukur HH, Hussain-Alkhateeb L, Farholt S, et al. Effects of Growth Hormone Treatment on Sleep-Related Parameters in Adults With Prader-Willi Syndrome. J Clin Endocrinol Metab 2021; 106:e3634.</a></li><li><a class="nounderline abstract_t">Noordam C, Höybye C, Eiholzer U. Prader-Willi Syndrome and Hypogonadism: A Review Article. Int J Mol Sci 2021; 22.</a></li><li><a class="nounderline abstract_t">McCandless SE, Committee on Genetics. Clinical report—health supervision for children with Prader-Willi syndrome. Pediatrics 2011; 127:195.</a></li><li><a class="nounderline abstract_t">Bakker NE, Wolffenbuttel KP, Looijenga LH, Hokken-Koelega AC. Testes in infants with Prader-Willi syndrome: human chorionic gonadotropin treatment, surgery and histology. J Urol 2015; 193:291.</a></li><li><a class="nounderline abstract_t">Greco D, Vetri L, Ragusa L, et al. Prader-Willi Syndrome with Angelman Syndrome in the Offspring. Medicina (Kaunas) 2021; 57.</a></li><li><a class="nounderline abstract_t">Donze SH, Kuppens RJ, Bakker NE, et al. Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial. Clin Endocrinol (Oxf) 2018; 88:806.</a></li><li><a class="nounderline abstract_t">Bakker NE, Kuppens RJ, Siemensma EP, et al. Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment. J Clin Endocrinol Metab 2015; 100:1609.</a></li><li><a class="nounderline abstract_t">Iughetti L, Vivi G, Balsamo A, et al. Thyroid function in patients with Prader-Willi syndrome: an Italian multicenter study of 339 patients. J Pediatr Endocrinol Metab 2019; 32:159.</a></li><li><a class="nounderline abstract_t">Pellikaan K, Snijders F, Rosenberg AGW, et al. Thyroid Function in Adults with Prader-Willi Syndrome; a Cohort Study and Literature Review. J Clin Med 2021; 10.</a></li><li><a class="nounderline abstract_t">Yang M, Ye J, Han L, et al. One-year follow-up of thyroid function in 23 infants with Prader- Willi syndrome at a single center in China. Intractable Rare Dis Res 2021; 10:198.</a></li><li><a class="nounderline abstract_t">Rosenberg AGW, Pellikaan K, Poitou C, et al. Central Adrenal Insufficiency Is Rare in Adults With Prader-Willi Syndrome. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Fintini D, Grugni G, Bocchini S, et al. Disorders of glucose metabolism in Prader-Willi syndrome: Results of a multicenter Italian cohort study. Nutr Metab Cardiovasc Dis 2016; 26:842.</a></li><li><a class="nounderline abstract_t">Pellikaan K, Rosenberg AGW, Kattentidt-Mouravieva AA, et al. Missed Diagnoses and Health Problems in Adults With Prader-Willi Syndrome: Recommendations for Screening and Treatment. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Miller J, Wagner M. Prader-Willi syndrome and sleep-disordered breathing. Pediatr Ann 2013; 42:200.</a></li><li><a class="nounderline abstract_t">Duis J, Pullen LC, Picone M, et al. Diagnosis and management of sleep disorders in Prader-Willi syndrome. J Clin Sleep Med 2022; 18:1687.</a></li><li><a class="nounderline abstract_t">Sedky K, Bennett DS, Pumariega A. Prader Willi syndrome and obstructive sleep apnea: co-occurrence in the pediatric population. J Clin Sleep Med 2014; 10:403.</a></li><li><a class="nounderline abstract_t">Canora A, Franzese A, Mozzillo E, et al. Severe obstructive sleep disorders in Prader-Willi syndrome patients in southern Italy. Eur J Pediatr 2018; 177:1367.</a></li><li><a class="nounderline abstract_t">Meyer SL, Splaingard M, Repaske DR, et al. Outcomes of adenotonsillectomy in patients with Prader-Willi syndrome. Arch Otolaryngol Head Neck Surg 2012; 138:1047.</a></li><li><a class="nounderline abstract_t">Pavone M, Paglietti MG, Petrone A, et al. Adenotonsillectomy for obstructive sleep apnea in children with Prader-Willi syndrome. Pediatr Pulmonol 2006; 41:74.</a></li><li><a class="nounderline abstract_t">Clements AC, Dai X, Walsh JM, et al. Outcomes of Adenotonsillectomy for Obstructive Sleep Apnea in Prader-Willi Syndrome: Systematic Review and Meta-analysis. Laryngoscope 2021; 131:898.</a></li><li><a class="nounderline abstract_t">Lee CH, Hsu WC, Ko JY, et al. Adenotonsillectomy for the Treatment of Obstructive Sleep Apnea in Children with Prader-Willi Syndrome: A Meta-analysis. Otolaryngol Head Neck Surg 2020; 162:168.</a></li><li><a class="nounderline abstract_t">Padia R, Muntz H, Pfeffer K, Meier J. Effectiveness of Adenotonsillectomy and Risk of Velopharyngeal Insufficiency in Children With Prader-Willi Syndrome. Ann Otol Rhinol Laryngol 2017; 126:733.</a></li><li><a class="nounderline abstract_t">Scheimann AO, Miller J, Glaze DG. Laparoscopic sleeve gastrectomy in children and adolescents with Prader-Willi syndrome: a matched control study. Surg Obes Relat Dis 2017; 13:366.</a></li><li><a class="nounderline abstract_t">Maas AP, Didden R, Bouts L, et al. Scatter plot analysis of excessive daytime sleepiness and severe disruptive behavior in adults with Prader-Willi syndrome: a pilot study. Res Dev Disabil 2009; 30:529.</a></li><li><a class="nounderline abstract_t">Bruni O, Verrillo E, Novelli L, Ferri R. Prader-Willi syndrome: sorting out the relationships between obesity, hypersomnia, and sleep apnea. Curr Opin Pulm Med 2010; 16:568.</a></li><li><a class="nounderline abstract_t">Camfferman D, McEvoy RD, O'Donoghue F, Lushington K. Prader Willi Syndrome and excessive daytime sleepiness. Sleep Med Rev 2008; 12:65.</a></li><li><a class="nounderline abstract_t">Helbing-Zwanenburg B, Kamphuisen HA, Mourtazaev MS. The origin of excessive daytime sleepiness in the Prader-Willi syndrome. J Intellect Disabil Res 1993; 37 ( Pt 6):533.</a></li><li><a class="nounderline abstract_t">Agar G, Brown C, Sutherland D, et al. Sleep disorders in rare genetic syndromes: a meta-analysis of prevalence and profile. Mol Autism 2021; 12:18.</a></li><li><a class="nounderline abstract_t">de Lind van Wijngaarden RF, de Klerk LW, Festen DA, Hokken-Koelega AC. Scoliosis in Prader-Willi syndrome: prevalence, effects of age, gender, body mass index, lean body mass and genotype. Arch Dis Child 2008; 93:1012.</a></li><li><a class="nounderline abstract_t">van Bosse HJP. Role of Body Cast Application for Scoliosis Associated With Prader-Willi Syndrome. J Pediatr Orthop 2021; 41:e321.</a></li><li><a class="nounderline abstract_t">Accadbled F, Odent T, Moine A, et al. Complications of scoliosis surgery in Prader-Willi syndrome. Spine (Phila Pa 1976) 2008; 33:394.</a></li><li><a class="nounderline abstract_t">Tokutomi T, Chida A, Asano Y, et al. A non-obese boy with Prader-Willi syndrome shows cardiopulmonary impairment due to severe kyphoscoliosis. Am J Med Genet A 2006; 140:1978.</a></li><li><a class="nounderline abstract_t">Trizno AA, Jones AS, Carry PM, Georgopoulos G. The Prevalence and Treatment of Hip Dysplasia in Prader-Willi Syndrome (PWS). J Pediatr Orthop 2018; 38:e151.</a></li><li><a class="nounderline abstract_t">Laumonerie P, Tibbo ME, Ibnoulkhatib A, et al. Evolution of Hip Dysplasia in Pediatric Patients With Prader-Willi Syndrome Treated With Growth Hormone Early in Development. J Pediatr Orthop 2020; 40:e357.</a></li><li><a class="nounderline abstract_t">Kroonen LT, Herman M, Pizzutillo PD, Macewen GD. Prader-Willi Syndrome: clinical concerns for the orthopaedic surgeon. J Pediatr Orthop 2006; 26:673.</a></li></ol></div><div id="topicVersionRevision">Topic 5864 Version 61.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Management of Prader-Willi Syndrome, Butler M, Lee PDK, Whitman BY (Eds), Springer-Verlag, New York 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29141973" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Energy Metabolism Profile in Individuals with Prader-Willi Syndrome and Implications for Clinical Management: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29141973" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Energy Metabolism Profile in Individuals with Prader-Willi Syndrome and Implications for Clinical Management: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33765021" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Characteristics and relationship between hyperphagia, anxiety, behavioral challenges and caregiver burden in Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30323638" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Obesity management in Prader-Willi syndrome: current perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34448208" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36181471" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35538810" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Willi Syndrome: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29925684" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Topline Results of the CARE-PWS Phase 3 Study: Intranasal Carbetocin Improves Hyperphagia and Anxiety and Distress Symptoms in Prader-Willi Syndrome (PWS)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24980612" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28100688" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The Use of Oxytocin to Improve Feeding and Social Skills in Infants With Prader-Willi Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35941105" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Oxytocin-based therapies for treatment of Prader-Willi and Schaaf-Yang syndromes: evidence, disappointments, and future research strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35941105" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Oxytocin-based therapies for treatment of Prader-Willi and Schaaf-Yang syndromes: evidence, disappointments, and future research strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33107433" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : MECHANISMS IN ENDOCRINOLOGY: Update on treatments for patients with genetic obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33647242" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15176917" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effects of topiramate in adults with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26584571" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31685813" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12915638" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15292365" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18603572" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23543664" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28556449" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35416416" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Critical review of bariatric surgical outcomes in patients with Prader-Willi syndrome and other hyperphagic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31515962" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bariatric surgery for Prader-Willi syndrome was ineffective in producing sustainable weight loss: Long term results for up to 10 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26431633" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Laparoscopic sleeve gastrectomy in children and adolescents with Prader-Willi syndrome: a matched-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35288862" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Patients with Prader-Willi Syndrome (PWS) Underwent Bariatric Surgery Benefit more from High-Intensity Home Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18162838" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Critical analysis of bariatric procedures in Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9079607" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Conversions and complications in 185 laparoscopic adjustable silicone gastric banding cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18449615" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : BioEnterics intragastric balloon for treatment of morbid obesity in Prader-Willi syndrome: specific risks and benefits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17036318" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Deaths due to choking in Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34748997" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The consequences of hyperphagia in people with Prader-Willi Syndrome: A systematic review of studies of morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9415471" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Acute idiopathic gastric dilation with gastric necrosis in individuals with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17667731" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Gastric rupture and necrosis in Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27854358" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Causes of death in Prader-Willi syndrome: Prader-Willi Syndrome Association (USA) 40-year mortality survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23329756" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Nutritional and metabolic findings in patients with Prader-Willi syndrome diagnosed in early infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34148559" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Behavioral features in Prader-Willi syndrome (PWS): consensus paper from the International PWS Clinical Trial Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26331980" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Autism spectrum disorder in Prader-Willi syndrome: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24076603" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Truncating mutations of MAGEL2 cause Prader-Willi phenotypes and autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16178933" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prader-Willi syndrome: intellectual abilities and behavioural features by genetic subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18665884" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Behavior in Prader-Willi syndrome: relationship to genetic subtypes and age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24311388" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : An open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30724590" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Guanfacine Extended Release for the Reduction of Aggression, Attention-Deficit/Hyperactivity Disorder Symptoms, and Self-Injurious Behavior in Prader-Willi Syndrome-A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29470292" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Rectal Picking Masquerading as Inflammatory Bowel Disease in Prader-Willi Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29470292" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Rectal Picking Masquerading as Inflammatory Bowel Disease in Prader-Willi Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21454045" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Psychiatric illness in a cohort of adults with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14723659" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cognitive abilities and genotype in a population-based sample of people with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1340242" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prader-Willi syndrome: a review with special attention to the cognitive and behavioral profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30658944" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Increased brain age in adults with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34945077" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hypogonadism in Women with Prader-Willi Syndrome-Clinical Recommendations Based on a Dutch Cohort Study, Review of the Literature and an International Expert Panel Discussion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34640379" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hypogonadism in Adult Males with Prader-Willi Syndrome-Clinical Recommendations Based on a Dutch Cohort Study, Review of the Literature and an International Expert Panel Discussion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18303077" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20980432" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Normal cortisol response to high-dose synacthen and insulin tolerance test in children and adults with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29959886" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : No central adrenal insufficiency found in patients with Prader-Willi syndrome with an overnight metyrapone test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7852523" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29666169" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Impact of transitional care on endocrine and anthropometric parameters in Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20395666" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Endocrine disorders in children with Prader-Willi syndrome--data from 142 children of the French database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33557878" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Time for a general approval of growth hormone treatment in adults with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26842920" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Growth Charts for Prader-Willi Syndrome During Growth Hormone Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21402637" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Growth standards of infants with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25489013" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Growth charts for non-growth hormone treated Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30697974" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A multidisciplinary approach to the clinical management of Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18697869" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Recommendations for the diagnosis and management of Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18697869" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Recommendations for the diagnosis and management of Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18697869" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Recommendations for the diagnosis and management of Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24001750" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28323917" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20849734" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25422026" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Growth hormone therapy, muscle thickness, and motor development in Prader-Willi syndrome: an RCT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23886754" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Growth hormone combined with child-specific motor training improves motor development in infants with Prader-Willi syndrome: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32411831" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Growth hormone treatment in Prader-Willi syndrome patients: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33222122" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Effects of growth hormone on cognitive, motor, and behavioral development in Prader-Willi syndrome children: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18031326" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20061431" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Long-term growth hormone therapy changes the natural history of body composition and motor function in children with prader-willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15192622" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Growth hormone and body composition in children younger than 2 years with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15580194" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11932286" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12713251" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Effects of 5 years growth hormone treatment in patients with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17062886" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34105729" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Growth Hormone Treatment for Adults With Prader-Willi Syndrome: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32580778" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Three years of growth hormone treatment in young adults with Prader-Willi syndrome: sustained positive effects on body composition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34204309" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Twenty Years of GH Treatment in Adults with Prader-Willi Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17326811" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Quality of life and psychological well-being in GH-treated, adult PWS patients: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27552545" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Beneficial Effects of GH in Young Adults With Prader-Willi Syndrome: A 2-Year Crossover Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30185718" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Visceral adipose tissue increases shortly after the cessation of GH therapy in adults with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24443368" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23433655" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Effects of growth hormone treatment in adults with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32609902" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Three years of growth hormone treatment in young adults with Prader-Willi Syndrome previously treated with growth hormone in childhood: Effects on glucose homeostasis and metabolic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27689944" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Metabolic health profile in young adults with Prader-Willi syndrome: results of a 2-year randomized, placebo-controlled, crossover GH trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27689944" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Metabolic health profile in young adults with Prader-Willi syndrome: results of a 2-year randomized, placebo-controlled, crossover GH trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27689944" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Metabolic health profile in young adults with Prader-Willi syndrome: results of a 2-year randomized, placebo-controlled, crossover GH trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19961030" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Sleep disordered breathing in infants with Prader-Willi syndrome during the first 6 weeks of growth hormone therapy: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32535587" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Sleep-Disordered Breathing in Children with Prader-Willi Syndrome in Relation to Growth Hormone Therapy Onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19158197" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19158197" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19158197" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19158197" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16770808" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Growth hormone therapy and scoliosis in patients with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33950234" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Effects of Growth Hormone Treatment on Sleep-Related Parameters in Adults With Prader-Willi Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33800122" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Prader-Willi Syndrome and Hypogonadism: A Review Article.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21187304" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Clinical report—health supervision for children with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25109686" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Testes in infants with Prader-Willi syndrome: human chorionic gonadotropin treatment, surgery and histology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34066798" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Prader-Willi Syndrome with Angelman Syndrome in the Offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29418016" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25668198" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30703060" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Thyroid function in patients with Prader-Willi syndrome: an Italian multicenter study of 339 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34501256" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Thyroid Function in Adults with Prader-Willi Syndrome; a Cohort Study and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34466342" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : One-year follow-up of thyroid function in 23 infants with Prader- Willi syndrome at a single center in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32232324" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Central Adrenal Insufficiency Is Rare in Adults With Prader-Willi Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27381990" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Disorders of glucose metabolism in Prader-Willi syndrome: Results of a multicenter Italian cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32877518" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Missed Diagnoses and Health Problems in Adults With Prader-Willi Syndrome: Recommendations for Screening and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24126982" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Prader-Willi syndrome and sleep-disordered breathing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35172921" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Diagnosis and management of sleep disorders in Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24733986" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Prader Willi syndrome and obstructive sleep apnea: co-occurrence in the pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29318372" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Severe obstructive sleep disorders in Prader-Willi syndrome patients in southern Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23165379" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Outcomes of adenotonsillectomy in patients with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16283627" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Adenotonsillectomy for obstructive sleep apnea in children with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33026674" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Outcomes of Adenotonsillectomy for Obstructive Sleep Apnea in Prader-Willi Syndrome: Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31818186" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Adenotonsillectomy for the Treatment of Obstructive Sleep Apnea in Children with Prader-Willi Syndrome: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28895429" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Effectiveness of Adenotonsillectomy and Risk of Velopharyngeal Insufficiency in Children With Prader-Willi Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27692916" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Laparoscopic sleeve gastrectomy in children and adolescents with Prader-Willi syndrome: a matched control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18790602" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Scatter plot analysis of excessive daytime sleepiness and severe disruptive behavior in adults with Prader-Willi syndrome: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20814307" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Prader-Willi syndrome: sorting out the relationships between obesity, hypersomnia, and sleep apnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18201664" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Prader Willi Syndrome and excessive daytime sleepiness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8123999" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : The origin of excessive daytime sleepiness in the Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33632309" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Sleep disorders in rare genetic syndromes: a meta-analysis of prevalence and profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18263693" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Scoliosis in Prader-Willi syndrome: prevalence, effects of age, gender, body mass index, lean body mass and genotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33122491" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Role of Body Cast Application for Scoliosis Associated With Prader-Willi Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18277871" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Complications of scoliosis surgery in Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16906551" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : A non-obese boy with Prader-Willi syndrome shows cardiopulmonary impairment due to severe kyphoscoliosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29309382" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : The Prevalence and Treatment of Hip Dysplasia in Prader-Willi Syndrome (PWS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31479030" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Evolution of Hip Dysplasia in Pediatric Patients With Prader-Willi Syndrome Treated With Growth Hormone Early in Development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16932110" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Prader-Willi Syndrome: clinical concerns for the orthopaedic surgeon.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
